Iovance Biotherapeutics shares fall 2.06% premarket after appointing Corleen Roche as CFO.

Iovance Biotherapeutics, Inc. fell 2.06% in premarket trading. The company announced the appointment of Corleen Roche as Chief Financial Officer (CFO), effective August 6, 2025. Ms. Roche brings over 30 years of experience in the biotech and life sciences industry, including executive financial leadership roles in publicly traded companies. Her previous roles include CFO positions at CG Oncology, Immunome, Biogen, CSL Behring, Sandoz, Wyeth, and Pfizer.